Department of Cardiology, Institute of Medicine, University of Tsukuba, Japan.
Department of Cardiology, Tsukuba Medical Center Hospital, Japan.
Intern Med. 2024 Sep 1;63(17):2433-2437. doi: 10.2169/internalmedicine.3065-23. Epub 2024 Feb 1.
A 67-year-old woman with severe aortic stenosis (AS) was transferred to our hospital for large B-cell lymphoma treatment. Because of her high risk of anthracycline-induced cardiotoxicity due to severe AS and low performance status, the patient was initially treated with doxorubicin-free chemotherapy. However, doxorubicin was considered necessary to achieve complete remission. After multidisciplinary team discussions, transcatheter aortic valve replacement (TAVR) was performed without complications. Nine days after TAVR, the patient received the first cycle of anthracycline-containing chemotherapy (R-CHOP). Currently, 12 months after completing 4 cycles of R-CHOP, the patient remains in complete remission without having developed cardiotoxicity.
一位 67 岁的女性,患有严重的主动脉瓣狭窄(AS),被转至我院接受大 B 细胞淋巴瘤的治疗。由于严重 AS 和较差的身体状态导致她有很高的蒽环类药物诱导性心脏毒性风险,所以初始给予她不含蒽环类药物的化疗。然而,为了达到完全缓解,考虑使用蒽环类药物。经多学科团队讨论后,进行了经导管主动脉瓣置换术(TAVR),没有出现并发症。在 TAVR 术后 9 天,患者接受了第一个周期含蒽环类药物的化疗(R-CHOP)。目前,完成 4 个周期 R-CHOP 后 12 个月,患者仍处于完全缓解状态,未发生心脏毒性。